Supply Chain Intelligence

Evofem Biosciences, Inc. Supply Chain

EVFM supply chain intelligence for Evofem Biosciences, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

EVFM ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

9Suppliers
9Customers
2Debt Items
20Related Chains

Evofem Biosciences, Inc. Suppliers

TickerNameConfidenceEvidence
CLOVIS-DAVIS-PHARMACEUTICALS-LLC CLOVIS-DAVIS-PHARMACEUTICALS-LLC 92% Under the distributorship agreement, Clovis Davis will lead the distribution, promotion, marketing, and sales of SOLOSEC within the Territory.
WINDTREE-THERAPEUTICS-INC WINDTREE-THERAPEUTICS-INC 92% On March 20, 2025, Windtree Therapeutics, Inc. (Windtree) and the Company entered into a License and Supply Agreement, as amended on March 28, 2025 (collectively, the Windtree License and Supply Agre…
WINT Windtree Therapeutics, Inc. 90% Reciprocal relationship from WINT graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from WINT graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from WINT g…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from EVFM graph: umber of sales employees; this negati…
JNJ Johnson & Johnson 72% umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any failure or future delay in the timely development of our internal commercializatio…
MRK Merck & Co., Inc. 72% umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any failure or future delay in the timely development of our internal commercializatio…
MRK Merck & Co., Inc. 72% Reciprocal relationship from MRK graph: Reciprocal relationship from EVFM graph: umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any f…
ORANY ORANY 72% n such a competitor or third party would then be able to introduce a competitive generic product onto the market once any available regulatory exclusivity has expired. The FDA has broad discretion in…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from EVFM graph: n such a competitor or third party would then be able to introduce a competitive generic product onto the market onc…

Evofem Biosciences, Inc. Customers

TickerNameConfidenceEvidence
WINTW WINDTREE THERAPEUTICS INC C/WTS 92% Reciprocal relationship from WINTW graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from WINTW graph: Pursuant to the L&S Agreement, we will act as the supplier to Evofem of it…
PHARMA-1 PHARMA-1 90% and, in the UAE, its licensee, Pharma 1.
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from EVFM graph: umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any f…
JNJ Johnson & Johnson 72% umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any failure or future delay in the timely development of our internal commercializatio…
MRK Merck & Co., Inc. 72% Reciprocal relationship from MRK graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from MRK graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from MRK grap…
MRK Merck & Co., Inc. 72% umber of sales employees; this negatively impacted our ability to maintain our sales and marketing capabilities. Any failure or future delay in the timely development of our internal commercializatio…
ORANY ORANY 72% n such a competitor or third party would then be able to introduce a competitive generic product onto the market once any available regulatory exclusivity has expired. The FDA has broad discretion in…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from EVFM graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from EVFM graph: n such a competitor or third part…
WINT Windtree Therapeutics, Inc. 72% Reciprocal relationship from WINT graph: rsuant to the terms of the warrant agreement, the exercise price of the July 2024 Warrants originally issued in connection with the Series C Preferred Stock w…

Evofem Biosciences, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
EVFM-DEBT-9389 Warrants outstanding: 263062097 90% xbrl warrant detail from xbrl 2026-03-31.
EVFM-DEBT-9390 Xbrl Convertible 90% xbrl convertible detail from xbrl 2024-12-31.

Evofem Biosciences, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Evofem Biosciences, Inc..

Evofem Biosciences, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Evofem Biosciences, Inc..

Evofem Biosciences, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
MRK Merck & Co., Inc. 100.00 1 ['customer', 'supplier']
WINTW WINDTREE THERAPEUTICS INC C/WTS 100.00 1 ['customer']
JNJ Johnson & Johnson 100.00 1 ['customer', 'supplier']
ORANY ORANGE 100.00 1 ['customer', 'supplier']
WINT Windtree Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
CPRX Catalyst Pharmaceuticals, Inc. 50.00 2
CYCN Cyclerion Therapeutics, Inc. 50.00 2
BLTE Belite Bio, Inc 50.00 2
CTMX CytomX Therapeutics, Inc. 50.00 2
AYTU Aytu BioPharma, Inc. 50.00 2
ANIK Anika Therapeutics, Inc. 50.00 2
D Dominion Energy, Inc. 50.00 2
DARE Daré Bioscience, Inc. 50.00 2
EXOZ eXoZymes, Inc. 50.00 2
AMZE Amaze Holdings, Inc. 50.00 2
CANF Can-Fite BioPharma Ltd. 50.00 2
BNBX BNB Plus Corp. 50.00 2
CYTOF Altamira Therapeutics Ltd. 50.00 2
DFTX Definium Therapeutics, Inc. 50.00 2
AVBP ArriVent BioPharma, Inc. 50.00 2
View EVFM supply chain intel →

Explore the full interactive supply chain map for Evofem Biosciences, Inc..

Open EVFM supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map